These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 39094629)

  • 1. Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics.
    Cao Y; Sutera P; Silva Mendes W; Yousefi B; Hrinivich T; Deek M; Phillips R; Song D; Kiess A; Cem Guler O; Torun N; Reyhan M; Sawant A; Marchionni L; Simone NL; Tran P; Onal C; Ren L
    Radiother Oncol; 2024 Oct; 199():110443. PubMed ID: 39094629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.
    Sutera P; Deek MP; Deek RA; Guler OC; Hurmuz P; Reyhan M; Rowe S; Radwan N; Dipasquale S; Hrinivich WT; Lowe K; Ren L; Saraiya B; Ennis R; Hathout L; Mayer T; Deweese TL; Song DY; Kiess A; Oymak E; Pienta K; Feng F; Pomper M; Ozyigit G; Tran PT; Onal C; Phillips RM
    Adv Radiat Oncol; 2024 Jul; 9(7):101507. PubMed ID: 38799104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision-support for treatment with
    Moazemi S; Erle A; Khurshid Z; Lütje S; Muders M; Essler M; Schultz T; Bundschuh RA
    Ann Transl Med; 2021 May; 9(9):818. PubMed ID: 34268431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment.
    Bianchi L; Ceci F; Balestrazzi E; Costa F; Droghetti M; Piazza P; Pissavini A; Presutti M; Farolfi A; Mei R; Castellucci P; Gandaglia G; Larcher A; Robesti D; Mottrie A; Briganti A; Morganti AG; Fanti S; Montorsi F; Schiavina R; Brunocilla E
    Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine learning-based prediction of invisible intraprostatic prostate cancer lesions on
    Yi Z; Hu S; Lin X; Zou Q; Zou M; Zhang Z; Xu L; Jiang N; Zhang Y
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1523-1534. PubMed ID: 34845536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligometastatic Prostate Cancer Treated with Metastasis-Directed Therapy Guided by Positron Emission Tomography: Does the Tracer Matter?
    Lanfranchi F; Belgioia L; Marcenaro M; Zanardi E; Timon G; Riondato M; Giasotto V; Zawaideh JP; Tomasello L; Mantica G; Piol N; Borghesi M; Traverso P; Satragno C; Panarello D; Scaffidi C; Romagnoli A; Rebuzzi SE; Coco A; Spina B; Morbelli S; Sambuceti G; Terrone C; Barra S; Fornarini G; Bauckneht M
    Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine learning-based analysis of [
    Cysouw MCF; Jansen BHE; van de Brug T; Oprea-Lager DE; Pfaehler E; de Vries BM; van Moorselaar RJA; Hoekstra OS; Vis AN; Boellaard R
    Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):340-349. PubMed ID: 32737518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
    Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
    Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ML Models Built Using Clinical Parameters and Radiomic Features Extracted from
    Urso L; Cittanti C; Manco L; Ortolan N; Borgia F; Malorgio A; Scribano G; Mastella E; Guidoboni M; Stefanelli A; Turra A; Bartolomei M
    Diagnostics (Basel); 2024 Jun; 14(12):. PubMed ID: 38928679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.
    Sheikh GT; Trapp C; Schmidt-Hegemann NS; Buchner A; Stief CG; Unterrainer M; Kunz WG; Cyran CC; Grawe F; Delker A; Zacherl MJ; Holzgreve A; Unterrainer LM; Brendel M; Belka C; Li M; Rogowski P
    EJNMMI Rep; 2024 Aug; 8(1):25. PubMed ID: 39155339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes of metastasis-directed treatment using
    Hurmuz P; Onal C; Ozyigit G; Igdem S; Atalar B; Sayan H; Akgun Z; Kurt M; Ozkok HB; Selek U; Oymak E; Tilki B; Guler OC; Mustafayev TZ; Saricanbaz I; Rzazade R; Akyol F
    Strahlenther Onkol; 2020 Nov; 196(11):1034-1043. PubMed ID: 32617620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.
    Deek MP; Sutera P; Jing Y; Gao R; Rothman E; Day H; Chang D; Dirix P; Armstrong AJ; Campbell B; Lopez Campos F; Berenguer M; Ramotar M; Conde-Moreno A; Berlin A; Bosetti DG; Corcoran N; Koontz B; Mercier C; Siva S; Pryor D; Ost P; Huynh MA; Kroeze S; Stish B; Kiess A; Trock B; Tran PT; Gillessen S; Sweeney C
    Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38570239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis.
    Glicksman RM; Metser U; Vines D; Valliant J; Liu Z; Chung PW; Bristow RG; Finelli A; Hamilton R; Fleshner NE; Perlis N; Zlotta AR; Green D; Bayley A; Helou J; Raman S; Kulkarni G; Catton C; Lam T; Chan R; Warde P; Gospodarowicz M; Jaffray DA; Berlin A
    Eur Urol; 2021 Sep; 80(3):374-382. PubMed ID: 33685838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oligometastatic Bone Disease in Castration-Sensitive Prostate Cancer Patients Treated With Stereotactic Body Radiotherapy Using 68Ga-PSMA PET/CT: TROD 09-004 Study.
    Onal C; Ozyigit G; Akgun Z; Atalar B; Igdem S; Oymak E; Agaoglu F; Selek U; Guler OC; Hurmuz P; Mustafayev TZ; Akyol F
    Clin Nucl Med; 2021 Jun; 46(6):465-470. PubMed ID: 33661210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer.
    Deijen CL; Vrijenhoek GL; Schaake EE; Vogel WV; Moonen LMF; Pos FJ; van der Poel HG; Borst GR
    Clin Transl Radiat Oncol; 2021 Sep; 30():1-6. PubMed ID: 34278008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
    Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
    Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a radiomics nomogram derived from Fluoride-18 PSMA-1007 PET/CT for risk stratification in newly diagnosed prostate cancer.
    Wang Z; Li Y; Zheng A; Gao J; Yuan W; Shen C; Bai L; Duan X
    Front Oncol; 2022; 12():1018833. PubMed ID: 36457489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multicenter Prospective Clinical Trial of
    McCarthy M; Francis R; Tang C; Watts J; Campbell A
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.